To see if Gene-Eden-VIR/Novirin is effective against genital herpes, Dr. Hanan Polansky, Dr. Edan Itzkovitz, and Adrian Javaherian, from the Center for the Biology of Chronic Disease (CBCD), conducted several clinical studies.  The studies followed FDA guidelines.

The first clinical study was published in the medical journal Drug Design, Development and Therapy.  The treatment included 1, 2, 3, or 4 capsules of Gene-Eden-VIR/Novirin per day.  Each capsule includes 100 mg of a quercetin extract, 150 mg of a green tea extract, 50 mg of a cinnamon extract, 25 mg of a licorice extract, and 100 mcg of selenium.  The treatment lasted between 2 to 48 months.  The study included 139 participants.  All participants had at least one genital herpes outbreak per year. 64 were male and 55 female.  The participants had suffered genital herpes outbreaks for periods ranging from 6 month to 40 years. 100 participants had genital blisters/ulcers, 22 anal blisters/ulcers, 28 burning feeling while urinating, 84 local pain, 12 genital discharge, 62 general discomfort, 23 light sensitivity, 78 genital tingling sensation, 81 genital itching sensation, 55 flu-like symptoms, 21 irritation (including burning), 18 redness, 4 fatigue, and 10 lower extremity pain.

 

The study showed Gene-Eden-VIR/Novirin was effective in decreasing the number of outbreaks in 90.8% of the participants.  Also, the study showed that after 12 months of treatment, Gene-Eden-VIR/Novirin stopped the herpes outbreaks in 42% of the cases. In addition, the study showed that in 73% of the cases, Gene-Eden-VIR/Novirin reduced the number of herpes outbreaks by more than 50%. The study also compared Gene-Eden-VIR/Novirin to acyclovir, valacyclovir, and famciclovir, the three leading drugs against genital herpes.  The results showed that Gene-Eden-VIR/Novirin is more effective and safer than the leading drugs.*†

To quote from the study:  “The clinical study showed that the natural Gene-Eden-VIR/Novirin decreases the number of genital herpes outbreaks without any side effects. The study also showed that the clinical effects reported in this study are mostly better than those reported in the reviewed studies of acyclovir, valacyclovir, and famciclovir.”*†

The study was published in the medical journal Drug Design, Development and Therapy, Volume 2017:11 Pages 575-583.

The second clinical study was published in the medical journal Clinical and Translational Medicine. The treatment, the duration of the study, the number of participants, and the symptoms of genital herpes, were similar to those reported in the first study.

The study showed Gene-Eden-VIR/Novirin was effective in decreasing the duration of outbreaks in 87% of the participants.  The participants had no side effects.*†

To quote from the study: “This paper shows that suppressive treatment with Gene-Eden-VIR/Novirin decreased the duration of genital herpes outbreaks, in both severe and mild cases, without any side effects. Based on the results reported in this and our previous paper, we recommend suppressive treatment with Gene-Eden-VIR/Novirin as a natural alternative to both suppressive and episodic treatments with current drugs, in both severe and mild genital herpes cases.”*†

The study was published in the medical journal Clinical and Translation Medicine, 2016 Dec;5(1):40.